PPBT (Purple Biotech) Non Operating Income: $-15.93 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PPBT Purple Biotech Ltd PPBT
21 GF Score
Price $1.76
! 2 Warning Signs
View Full Analysis

What is Purple Biotech Non Operating Income?

Purple Biotech PPBT -2.82% 21 Non Operating Income is $-15.93 Mil as of Jun. 2026. GuruFocus rates PPBT with a GF Score™ of 21/100. The stock has 2 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Purple Biotech's Non Operating Income for the three months ended in Jun. 2026 was $1.67 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was $-15.93 Mil.

Purple Biotech Non Operating Income Related Terms

Purple Biotech Non Operating Income Historical Data

* Premium members only.

The historical data trend for Purple Biotech's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Purple Biotech Non Operating Income Chart

Purple Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Non Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.13 0.31 4.00 3.74 -18.77

Purple Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 -0.06 -19.72 2.17 1.67
PPBT
21GF Score
Purple Biotech Ltd PPBT
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Purple Biotech Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $-15.93 Mil mean?
Purple Biotech (PPBT) has a Non Operating Income of $-15.93 Mil as of Jun. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Purple Biotech and its competitors.
Is Purple Biotech's Non Operating Income too high?
Purple Biotech's current Non Operating Income is $-15.93 Mil. Overall, Purple Biotech has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Purple Biotech's Non Operating Income compare to VRTX and REGN?
Purple Biotech's Non Operating Income of $-15.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Biotechnology company?
A good Non Operating Income depends on the Biotechnology industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Purple Biotech and its competitors. Purple Biotech's current Non Operating Income is $-15.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Purple Biotech stock overvalued right now?
Purple Biotech (PPBT) has a current Non Operating Income of $-15.93 Mil. The current Non Operating Income is $-15.93 Mil. Purple Biotech's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Purple Biotech (PPBT), the current Non Operating Income is $-15.93 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Purple Biotech Business Description

Other Exchanges PPBT:Israel
Address 4 Oppenheimer Street, Science Park, Rehovot, ISR, 7670104
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.
21GF Score

Get the complete analysis for PPBT

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.76
Price